Table 1.
Maternal PMTCT results
| Variable (n, %) | Total (n=260) |
| HIV diagnosis time point* | |
| Before pregnancy | 182 (71.4) |
| During pregnancy | 72 (28.2) |
| After birth | 1† (0.4) |
| CD4 (during pregnancy) | |
| CD4 cells/mm3 (median) (IQR) | 411 (286–609) |
| ≥500 cells/ mm3 | 78 (30.0) |
| 350–500 cells/mm3 | 45 (17.3) |
| <350 cells/mm3 | 82 (31.5) |
| No CD4 reported during pregnancy | 55 (21.2) |
| Viral load (VL) (during pregnancy) | |
| Virally unsuppressed (≥1000 copies/mL) | 15 (5.8) |
| VL detectable (≥40–1000 copies/mL) | 28 (10.8) |
| VL lower than detectable limit (<40 copies/mL) | 105 (40.4) |
| No VL reported during pregnancy | 112 (43.1) |
| ART initiation* | |
| Before pregnancy | 98 (39.2) |
| During pregnancy | 150 (60.0) |
| Received ARVs during labour only | 2 (0.8) |
| ART regimen during pregnancy* | |
| PMTCT prophylaxis (AZT (zidovudine)) | 39 (15.6) |
| First-line ART (triple therapy) | 195 (78.0) |
| Second /third-line ART | 14 (5.6) |
| ARVs during labour only | 2 (0.8) |
| ART regimen switched during pregnancy* | 10 (4.0) |
| Evidence of defaulting any time during pregnancy* | 49 (19.6) |
Missing data: HIV diagnosis time point n=6; Antiretroviral therapy variables n=10.
*Percentages are calculated out of available data.
†This mother was diagnosed outside of the PMTCT pathway and as such she is not included in the other variables in this table.
ART, antiretroviral therapy; AZT, zidovudine;PMTCT, prevention of mother-to-child transmission; VL, viral load.